CVClaire Vandevelde

Claire Vandevelde

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claire Vandevelde has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Better communication between rheumatologists and radiologists is key to improving MRI requesting and reporting data in axial spondyloarthritis: audit data from a single specialist centre

    by Jake Weddell, Henry de Boer, Joshua Wong, Bill Pass, Philip Robinson, Andrew Barr, Claire Vandevelde, Jane E Freeston, Dennis McGonagle, Helena Marzo-Ortega

    Objectives: The assessment of axial spondyloarthritis international society (ASAS) has published recommendations on information to include when requesting and reporting MRIs for suspected or known axSpA. In a service improvement evaluation, we aimed to audit our current practice against the newly published recommendations. Methods: MRIs of the spine and sacroiliac joints performed under the inflammatory back pain protocol at The Leeds Teaching Hospitals NHS Trust between September and December 2023 were identified. Information included in the MRI request and radiology reports was extracted from the electronic health records. Results: Overall, 158 MRIs were evaluated. Of the MRI requests, age was included in 11.8% (n = 18), sex in 3.8% (n = 6); HLA-B27 in 22.2% (n = 35), back pain symptom duration in 18.9% (n = 30) and location in 45.6% (n = 72) and presence of inflammatory features in 62.7% (n = 99). For MRI report data: osteitis/bone marrow oedema was mentioned in 81.0% (n = 128), erosions in 58.8% (n = 93) and fat metaplasia in 6.3% (n = 10); active inflammation was mentioned in 77.8% (n = 123) and structural changes in 51.2% reports (n = 82). Over half (62.0%; n = 98) included a statement as to “whether the MRI was overall indicative of spondyloarthritis or not”. Conclusion: Despite the retrospective nature of this audit performed against newly published guidance, these results provide awareness, identifying key areas in need of improvement at our centre. Further, this exercise has strengthened the collaboration between rheumatologists and radiology colleagues, illustrating the value of the recent ASAS recommendations as a benchmark to guide further training and education for rheumatologists and radiologists, and improve clinical care provision in axSpA.

  • Comment on: FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan: reply

    by Katya Meridor, Stephanie R Harrison, Richard Parker, Ramu Chimakurthi, Philip M Laws, Dennis McGonagle, Andrew Barr, Claire Y Vandevelde, Helena Marzo-Ortega, Jane E Freeston

  • Open Access

    FIB-4 as an effective screening tool in psoriatic arthritis patients at high-risk for liver disease: a cross-sectional study using FibroScan

    by Katya Meridor, Stephanie R Harrison, Richard Parker, Chenchu Chimakurthi, Philip M Laws, Dennis McGonagle, Andrew Barr, Claire Y Vandevelde, Helena Marzo-Ortega, Jane E Freeston

    Objectives: To evaluate the performance of non-invasive screening tools in identifying metabolic dysfunction-associated steatotic liver disease (MASLD) causing clinically significant liver disease (CSLD) in PsA patients at high risk for liver disease, and to identify factors associated with CSLD. Methods: A single-centre, cross-sectional study of PsA patients referred for liver assessment due to suspected CSLD secondary to MASLD was conducted. Fibrosis-4 (FIB-4), Enhanced Liver Fibrosis (ELF) and BARD (BMI, aspartate aminotransferase/alanine transaminase ratio and Diabetes) scores were calculated using routine laboratory and clinical data. Liver imaging was performed as clinically indicated, including FibroScan in most patients. CSLD was defined as liver stiffness measurement (LSM) >10 kPa on FibroScan and/or US and/or biopsy showing steatosis/fibrosis/cirrhosis secondary to MASLD. Univariable and multivariable analyses identified variables independently associated with CSLD. Results: Eighty-nine PsA patients were included (median age 51.0 years; 57.3% male). Cardiometabolic comorbidities were common: 96.6% had one or more metabolic risk factor and 69.7% were obese. CSLD was identified in 55/89 patients (61.8%). In univariable analyses, hypertriglyceridaemia, hypertension, statin use, BMI >30 kg/m2, higher ELF and FIB-4 scores, and elevated LSM were significantly associated with CSLD. In multivariable regression, hypertension, BMI >30 kg/m2 and FIB-4 ≥1.3 remained independently associated. FIB-4 ≥1.3 demonstrated sensitivity of 47.8%, specificity of 77.2%, positive predictive value of 6.1% and negative predictive value of 98.0%. MTX exposure was not associated with CSLD. Conclusions: CSLD is common in high-risk PsA patients and strongly associated with metabolic risk factors. FIB-4 ≥1.3 had high negative predictive value, supporting its use as a first-line screening tool. Routine MASLD screening using a pathway incorporating FIB-4 followed by FibroScan may inform safer prescribing and improve outcomes.


  • Improving the delivery of multi-specialty care: the rise of the combined clinic service

    by Helena Marzo-Ortega, Eva Domanne, Evmorfia Ladoyanni, Adrian Victor Pace, Hoda Mirjafari-Temple, Jane E Freeston, Claire Vandevelde, Andrew Barr, Dennis McGonagle, Christian Selinger, et al.

  • Open Access

    Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis

    by Jake Weddell, Naw Ra Aung Din, Stephanie R Harrison, Xabier Michelena, Dennis McGonagle, Andrew Barr, Claire Vandevelde, Jane Freeston, Helena Marzo-Ortega

    Objective: The aim was to assess the use and drug survival of IL-17Ai in a real-world cohort of axial SpA (axSpA) and PsA patients. Methods: Patients ever commenced on an IL-17Ai (secukinumab or ixekizumab) for axSpA or PsA at the Leeds Specialist Spondyloarthritis Service were identified. Demographics, IL-17Ai treatment length and reason for cessation were collected. Drug survival data were plotted as a Kaplan–Meier curve, with log rank test of median survival compared between axSpA and PsA. Cox regression analysis was performed to investigate the relationship between diagnosis and length of drug survival. Results: In total, 228 patients (91 axSpA and 137 PsA) were exposed to IL-17Ai. Drug survival for all patients at 12 months was 69% (95% Confidence Interval (CI) 63, 75%) and at 24 months 60% (95% CI 54, 67%). In axSpA and PsA, drug survival at 12 months was 63% (CI 54, 74%) and 73% (CI 66, 81%), respectively, and at 24 months it was 53% (CI 44, 65%) and 65% (CI 57, 75%), respectively. Median survival did not differ significantly between both diseases (log rank test 0.65). There was no association between diagnosis and survival (hazard ratio 0.92, 95% CI 0.63, 1.33), including when adjusting for age, previous biologic DMARD usage and sex (hazard ratio 0.89, 95% CI 0.61, 1.13). Conclusion: This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.


  • Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input

    by Claire Y Vandevelde, Kate Harnden, Jane Freeston, Andrew Barr, Christian P Selinger, Kave Shams, Philip Laws, Helena Marzo-Ortega